---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-26-000008"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:23:42.054919+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines reports FY2025 revenue $5.34B, R&D spend $2.15B

## Summary
- Revenue $5.34B, up 40% YoY; gross margin 87.5% (China 66.6%, ex-China 97.0%)
- R&D total $2.15B, up 10% YoY; largest pipeline: sonrotoclax $176.7M, BRUKINSA $97.6M
- Key product production 6.27M vials, sales 5.99M vials; inventory 2.91M vials at Dec 31, 2025
- U.S. GAAP vs PRC GAAP differences: stock compensation and lease accounting treatments vary

## SEC filing metadata
- accession: 0001651308-26-000008
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000008/0001651308-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000008/bgne-20260414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-26-000008
- JSON: https://secwatch.observer/filing/0001651308-26-000008.json
- Plain text: https://secwatch.observer/filing/0001651308-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.